A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo

Cancer Immunology, Immunotherapy

Volumn 54, Issue 2, 2005, Pages 129-140

  Gückel, Brigitte ^a   Stumm, Susanne ^b   Rentzsch, Christine ^a   Marmé, Alexander ^b   Mannhardt, Geeske ^b   Wallwiener, Diethelm ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; Cellular vaccines; HER 2 neu; Immunotherapy; T cell diagnostic

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MUCIN 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANTIGENICITY; ARTICLE; BREAST CANCER; CANCER CELL; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INFLUENZA VIRUS A; MIXED LYMPHOCYTE CULTURE; NONHUMAN; ONCOGENE NEU; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VACCINATION;

ANTIGENS, CD80; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKINES; FEASIBILITY STUDIES; FEMALE; HLA-A ANTIGENS; HUMANS; INFLUENZA A VIRUS; K562 CELLS; LEUKOCYTES, MONONUCLEAR; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINATION; VIRAL MATRIX PROTEINS;

EID: 11944262611     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0583-z     Document Type: Article

References (58)

1. Arienti F, Belli F, Napolitano F, Sule-Suso J, Mazzocchi A, Gallino GF, Cattelan A, Santantonio C, Rivoltini L, Melani C, Colombo MP, Cascinelli N, Maio M, Parmiani G, Sanantonio C (2000) Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 10:2907-2916
2. Baskar S, Nabavi N, Glimcher LH, Ostrand-Rosenberg S (1993) Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J Immunother 14:209-215
3. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M (2004) Immunobiology of Her-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 53:166-175
4. Bednarek MA, Engl SA, Gammon MC, Lindquist JA, Porter G, Williamson AR, Zweerink HJ (1991) Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes. J Immunol Methods 139:41-47
5. Brossait P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317
6. Cayeux S, Beck C, Aicher A, Dorken B, Blankenstein T (1995) Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 25:2325-2331
7. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
8. Courmier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM (1999) Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 80:781-790
9. Crowley NJ, Slingluff CL Jr, Vervaert CE, Darrow TL, Seigler HF (1990) Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. J Surg Oncol 43:67-72
10. Deuschle U, Pepperkok R, Wang FB, Giordano TJ, McAllister WT, Ansorge W, Bujard H (1989) Regulated expression of foreign genes in mammalian cells under the control of coliphage T3 RNA polymerase and lac repressor. Proc Natl Acad Sci U S A 86(14):5400-5404
11. Dois A, Meijer SL, Smith JW II, Fox BA, Urba WJ (2003) Allogeneic breast cancer cell vaccines. Clin Breast Cancer 3[Suppl4]:173-180
12. Dois A, Smith JW II, Meijer SL, Fox BA, Hu HM, Walker E, Rosenheim S, Moudgil T, Doran T, Wood W, Seligman M, Alvord WG, Schoof D, Urba WJ (2003) Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancel-cell line: clinical and immunological results. Hum Gene Ther 14:1117-1123
13. Dois A, Meijer SL, Hu HM, Goodell V, Disiss ML, von Mensdorff-Pouilly S, Verheijen R, Alvord WG, Smith JW II, Urba WJ, Fox BA (2003) Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother 26:163-170
14. Fenton RG, Turcovski-Corrales SM, Taub DD (1998) Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. J Immunother 21:95-108
15. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of Her-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117
16. Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG, Kudelka AP (1997) Existent proliferative response of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to Her-2 peptides. Anticancer Res 17:45-53
17. Giuliano AE, Sparks FC, Patterson K, Spears I, Morton DL (1986) Adjuvant chemo-immunotherapy in stage II carcinoma of the breast. J Surg Oncol 31:255-259
18. Gückel B, Lindauer M, Rudy W, Habicht A, Siebels M, Kaul S, Bastert G, Meuer SC, Moebius U (1995) CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes. Cytokines Mol Ther 1:211-221
19. Gückel B, Meyer GC, Rudy W, Batrla R, Meuer SC, Bastert G, Wallwiener D, Moebius U (1999) Interleukin-12 requires initial CD80-medialed T-cell activation to support immune responses loward human breast and ovarian carcinoma. Cancer Gene Ther 6:228-237
20. Gückel B, Meuer S, Bastert G, Wallwiener D (2003) Tumor-associated antigens as tools in immunodiagnostics and immunotherapy of breast cancer. Geburtsh Frauenheilk 64:130-139
21. Habicht A, Lindauer M, Galmbacher P, Rudy W, Gebert J, Schackert HK, Meuer SC, Moebius U (1995) Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro. Eur J Cancer 31A:2396-2402
22. Hellström KE, Hellström I, Chen L (1995) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 145:123-145
23. Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178-186
24. Hirano N, Takahashi T, Takahashi T, Azuma M, Okumura K, Yazaki Y, Yagita H, Hirai H (1997) Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Hum Gene Ther 8:1375-1384
25. Imro MA, Dellabona P, Manici S, Heltai S, Consogno G, Bellone M, Rugarli C, Protti MP (1998) Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Hum Gene Ther 9:1335-1344
26. Jäger E, Jager D, Knuth A (1998) Strategies for the development of vaccines to treat breast cancer. Recent Results Cancer Res 152:94-102
27. Jiang XP, Yang DC, Elliott RL, Head JF (2000) Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125-results in immune and clinical responses in breast cancer patients. Cancer Biother Radiopharm 15:495-505
28. Jung D, Jaeger E, Cayeux S, Blankenstein T, Hilmes C, Karbach J, Moebius U, Knuth A, Huber C, Seliger B (1998) Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. Hum Gene Ther 9:53-62
29. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM (1999) Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 163:6867-6875
30. Kammula US, Marincola FM, Rosenberg SA (2000) Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 92:1336-1344
31. Kaufmann AM, Gissmann L, Schreckenberger C, Qiao L (1997) Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens. Cancer Gene Ther 4:377-382
32. Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B (2003) Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition? J Cancer Res Clin Oncol 129:397-409
33. Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG (1996) Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 6:299-306
34. Kruse N, Pette M, Toyka K, Rieckmann P (1997) Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods 210:195-203
35. Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L (1994) Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421-428
36. Lindauer M, Rudy W, Gückel B, Doeberitz MV, Meuer SC, Moebius U (1998) Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity. Immunology 93:390-397
37. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA (1997) Identification of Her-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum Immunol 52:109-118
38. Meuer SC, Gückel B, Lindauer M, Rudy W, Moebius U (1998) Construction of immunogenic tumor cell surfaces by somatic gene transfer. Recent Results Cancer Res 144:78-85
39. Meyer GC, Batrla R, Rudy W, Meuer SC, Wallwiener D, Gückel B, Moebius U (1999) Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1 + -matched situation. Cancer Gene Ther 6:282-288
40. Osanto S, Schiphorst PP, Weijl NI, Dijkstra N, Van Wees A, Brouwenstein N, Vaessen N, Van Krieken JH, Hermans J, Cleton FJ, Schrier PI (2000) Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther 11:739-750
41. Pascolo S, Schirle M, Gückel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee H-G, Stevanović S (2001) A MAGE-A1 HLA-A*0201 epitope identified by mass spectrometry. Cancer Res 61:4072-4077
42. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A 90:4645-4649
43. Rammensee HG, Bachmann J, Emmerich NN, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219. http:// www.uni-tuebingen.de/uni/kxi/
44. Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanoviæ S, Wallwiener D, Gückel B (2003) Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 9:4376-4386
45. Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM (2000) Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer 86:818-826
46. Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539-542
47. Salcedo M, Momburg F, Hämmerling GJ, Ljunggren HG (1994) Resistance to natural killer cell lysis conferred TAP1/2 genes in human antigen-processing mutant cells. J Immunol 152:1702-1708
48. Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K (2001) Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31:3261-3270
49. Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nobetaner E, Willimsky G, Maget B, Pohla H, Blankenstein T (2000) Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7:2007-2014
50. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG (2000) Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216-2225
51. Schmidt W, Buschle M, Zauner W, Kirlappos H, Mechtler K, Trska B, Birnstiel ML (1997) Cell-free tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci U S A 94:3262-3267
52. Stevens EJ, Jacknin L, Robbins PF, Kawakami Y, el Gamil M, Rosenberg SA, Yannelli JR (1995) Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: fine specificity and MART-1 melanoma antigen recognition. J Immunol 154:762-771
53. Sundquist M, Thorstenson S, Brudin L, Wingren S, Nordenskjold B (2002) Incidence and prognosis in early onset breast cancer. Breast 11:30-35
54. Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM (1996) Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 56:3782-3787
55. + T cells by B7-transfected melanoma cells. Science 259:368-370
56. Wang YC, Zhu L, McHugh R, Graham SD Jr, Hillyer CD, Dillehay D, Sell KW, Selvaraj P (1996) Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. J Immunother Emphasis Tumor Immunol 19:1-8
57. Wiseman C, Jessup JM, Smith TL, Hersh E, Bowen J, Blumenshein G (1982) Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy. Cancer 49:1266-1271
58. Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu + tumors. Cancer 58:4902-4908